Funding
Funding not disclosed
Founders
Product
Problem
Current metallic vascular stents can cause long-term complications such as in-stent restenosis and late stent thrombosis, while existing resorbable stents often lack the necessary mechanical strength and controlled drug delivery. This necessitates a temporary support structure that promotes healing without permanent implantation or long-term adverse effects.
Solution
Hartlon is developing a multilayer, drug-eluting, bioresorbable vascular stent designed to provide temporary radial support to newly opened arteries during percutaneous coronary intervention (PCI). The stent is constructed from a high molecular weight poly lactic acid, enabling thin struts that slowly dismantle during resorption. Its multilayer design facilitates controlled release of therapeutic drugs, minimizing scar tissue formation without interfering with the healing process. Once the artery has healed, the Hartlon stent dissolves, leaving the artery open and in its natural state, eliminating the long-term risks associated with permanent metallic stents.
Target Audience
The primary target audience includes interventional cardiologists and vascular surgeons seeking advanced stent technology for patients undergoing percutaneous coronary intervention (PCI) to treat artery disease.
Features
- Multilayer construct for controlled drug elution
- High molecular weight poly lactic acid material for enhanced strength and controlled resorption
- Thin struts to minimize vessel injury and promote endothelialization
- Temporary radial support during artery healing
- Bioresorbable material that dissolves completely after the healing process
- Designed to minimize scar tissue formation